Kinase inhibitor market

Oncodesign opens up a path to new kinases of therapeutic interest

The kinase inhibitors are molecules representing a market estimated at over $40 to $60 billion in 2016 and accounting for close to 25% of R&D investments across the pharmaceutical industry as a whole. The reason why they are so important is that they can block the action of deregulated kinases. Kinases are enzymes that regulate organisms, and when thrown out of kilter, they can cause over 400 diseases, including a large number of cancers.

Unlike those already on the market, Oncodesign is developing a new generation of highly targeted kinase inhibitors that curb the side effects of treatment for patients. Oncodesign’s technology can be used to develop small macrocyclic molecules, which are highly specific and rigid owing to their 3-dimensional form that is highly suitable for selectively inhibiting the kinase responsible for the disease. 

Oncodesign has focused its attention on several kinases of interest with tremendous potential in oncology (cancer of the ovaries, pancreas, glioblastoma, etc.) and in other therapeutic areas (Parkinson’s disease, Crohn’s disease, arthritis, psoriasis, etc.).